{
  "id": "mhgap#screening_cues_32228306",
  "content": "Justification Remarks\ny Data were extracted from an NMA: Yildiz et al., 2023 y Please refer to recommendation PSY8 to find\n(101 RCTs on pharmacotherapy for adults with further information on the recommendations\nbipolar depression) (207). for mood stabilizer and antipsychotic use in\ny The study showed small effects for reduction maintenance treatment.\nof depressive symptoms for the combination of\nResearch gaps\nolanzapine plus fluoxetine with moderate certainty\nof evidence (SMD = 0.41). Venlafaxine showed small y Most of the evidence is from HICs. Further research is\neffects as well (SMD = 0.47) with low certainty of needed in LMICs.\nevidence. Fluoxetine showed large effects (SMD y Most of the available data are for antipsychotics;\n= 0.75), based however on very low certainty more data are needed on antidepressants.\nof evidence.\nImplementation considerations\ny The other investigated (adjunctive) psychotropic\ny People living with bipolar disorders should\nmedicines with antidepressive use (including\nbe involved in medicine choice in a supported\nantidepressants, mood stabilizers and\ndecision-making process.\nantipsychotics), namely sertraline, paroxetine,\nimipramine, aripiprazole plus citalopram, sertraline y Acquisition costs can differ substantially and also\nplus lithium, bupropion, citalopram and risperidone throughout the world.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "screening_cues",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Screening Cues Justification Remarks\ny Data were extracted from an NMA: Yildiz et al., 2023 y Please refer to recommendation PSY8 to find\n(101 RCTs on pharmacotherapy for adults with further information on the recommendations\nbipolar depression) (207). for mood stabilizer and antipsychotic use in\ny The study showed small effects for reduction maintenance treatment.\nof depressive symptoms for the combination of\nResearch gaps\nolanzapine plus fluoxetine with moderate certainty\nof evidence (SMD = 0.41). Venlafaxine showed small y Most of the evidence is from HICs. Further research is\neffects as well (SMD = 0.47) with low certainty of needed in LMICs.\nevidence. Fluoxetine showed large effects (SMD y Most of the available data are for antipsychotics;\n= 0.75), based however on very low certainty more data are needed on antidepressants.\nof evidence.\nImplementation considerations\ny The other investigated (adjunctive) psychotropic\ny People living with bipolar disorders should\nmedicines with antidepressive use (including\nbe involved in medicine choice in a supported\nantidepressants, mood stabilizers and\ndecision-making process.\nantipsychotics), namely sertraline, paroxetine,\nimipramine, aripiprazole plus citalopram, sertraline y Acquisition costs can differ substantially and also\nplus lithium, bupropion, citalopram and risperidone throughout the world. Justification remarks\ny data were extracted from an nma: yildiz et al., 2023 y please refer to recommendation psy8 to find\n(101 rcts on pharmacotherapy for adults with further information on the recommendations\nbipolar t..."
}